Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Acorda's MS Drug Amaya Panel Review Leaves Little Time To React

This article was originally published in The Pink Sheet Daily

Executive Summary

The Peripheral and Central Nervous System Drugs Advisory Committee will review the mobility-enhancing drug one week before its scheduled PDUFA date.

You may also be interested in...

Schering Likely To Play Up Saphris' Safety In Q4 Launch

Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.

Schering Plough's Saphris Gets Strong Nod From FDA Panel

A safety profile showing less impact on weight and metabolic parameters than other atypical antipsychotics could set asenapine apart in crowded class if it is approved.

Biogen Idec/Acorda Strike Licensing Deal For MS Candidate Fampridine-SR

Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts